Nifty
Sensex
:
:
17739.85
60384.62
-24.75 (-0.14%)
-122.28 (-0.20%)

Pharmaceuticals & Drugs - Domestic

Rating :
50/99

BSE: 531599 | NSE: FDC

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,322.79
  • 25.56
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,291.71
  • N/A
  • 2.27

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.49%
  • 1.74%
  • 15.43%
  • FII
  • DII
  • Others
  • 3.77%
  • 7.65%
  • 1.92%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.05
  • 7.28
  • 4.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.44
  • 2.28
  • -2.84

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.38
  • 4.46
  • -3.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.06
  • 19.16
  • 19.06

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.99
  • 2.77
  • 2.80

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.13
  • 12.99
  • 13.24

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
444.99
397.62
11.91%
494.66
447.47
10.55%
341.05
313.40
8.82%
341.78
340.23
0.46%
Expenses
377.66
326.41
15.70%
416.66
332.00
25.50%
321.84
261.79
22.94%
293.98
266.50
10.31%
EBITDA
67.32
71.21
-5.46%
78.00
115.47
-32.45%
19.21
51.61
-62.78%
47.81
73.73
-35.16%
EBIDTM
15.13%
17.91%
15.77%
25.80%
5.63%
16.47%
13.99%
21.67%
Other Income
12.73
30.38
-58.10%
19.12
23.20
-17.59%
9.67
14.97
-35.40%
12.84
35.05
-63.37%
Interest
1.02
0.73
39.73%
0.72
0.81
-11.11%
0.70
1.07
-34.58%
0.85
0.80
6.25%
Depreciation
9.98
9.49
5.16%
9.36
9.56
-2.09%
9.21
9.54
-3.46%
9.04
9.19
-1.63%
PBT
69.06
91.37
-24.42%
87.05
128.30
-32.15%
18.97
53.85
-64.77%
50.75
98.78
-48.62%
Tax
17.26
19.04
-9.35%
16.39
30.46
-46.19%
8.58
7.09
21.02%
15.14
23.57
-35.77%
PAT
51.79
72.32
-28.39%
70.66
97.84
-27.78%
10.39
46.76
-77.78%
35.61
75.21
-52.65%
PATM
11.64%
18.19%
14.28%
21.86%
3.05%
14.92%
10.42%
22.11%
EPS
3.12
4.29
-27.27%
4.26
5.80
-26.55%
0.62
2.78
-77.70%
2.11
4.46
-52.69%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
1,622.48
1,527.92
1,333.20
1,344.19
1,090.70
1,075.07
1,013.87
994.32
889.31
845.85
772.83
Net Sales Growth
8.26%
14.61%
-0.82%
23.24%
1.45%
6.04%
1.97%
11.81%
5.14%
9.45%
 
Cost Of Goods Sold
595.80
530.21
414.07
425.72
345.14
352.08
339.05
357.93
272.91
266.16
311.11
Gross Profit
1,026.68
997.71
919.14
918.46
745.56
722.99
674.81
636.38
616.40
579.69
461.71
GP Margin
63.28%
65.30%
68.94%
68.33%
68.36%
67.25%
66.56%
64.00%
69.31%
68.53%
59.74%
Total Expenditure
1,410.14
1,274.23
999.15
1,051.25
859.68
848.38
770.40
765.58
690.76
641.47
591.97
Power & Fuel Cost
-
28.91
27.08
27.40
24.61
22.00
21.55
23.14
20.18
18.45
16.85
% Of Sales
-
1.89%
2.03%
2.04%
2.26%
2.05%
2.13%
2.33%
2.27%
2.18%
2.18%
Employee Cost
-
343.33
296.29
277.48
225.57
216.67
191.08
175.76
137.58
122.05
107.52
% Of Sales
-
22.47%
22.22%
20.64%
20.68%
20.15%
18.85%
17.68%
15.47%
14.43%
13.91%
Manufacturing Exp.
-
102.98
77.97
68.80
62.25
58.77
49.40
36.44
97.27
88.65
22.88
% Of Sales
-
6.74%
5.85%
5.12%
5.71%
5.47%
4.87%
3.66%
10.94%
10.48%
2.96%
General & Admin Exp.
-
70.29
55.64
58.06
59.45
61.55
53.35
49.97
41.43
35.99
34.32
% Of Sales
-
4.60%
4.17%
4.32%
5.45%
5.73%
5.26%
5.03%
4.66%
4.25%
4.44%
Selling & Distn. Exp.
-
147.96
87.74
94.70
78.92
75.96
64.36
57.73
64.96
58.43
56.15
% Of Sales
-
9.68%
6.58%
7.05%
7.24%
7.07%
6.35%
5.81%
7.30%
6.91%
7.27%
Miscellaneous Exp.
-
50.55
40.37
99.07
63.73
61.35
51.61
64.61
56.43
51.73
56.15
% Of Sales
-
3.31%
3.03%
7.37%
5.84%
5.71%
5.09%
6.50%
6.35%
6.12%
5.58%
EBITDA
212.34
253.69
334.05
292.94
231.02
226.69
243.47
228.74
198.55
204.38
180.86
EBITDA Margin
13.09%
16.60%
25.06%
21.79%
21.18%
21.09%
24.01%
23.00%
22.33%
24.16%
23.40%
Other Income
54.36
76.09
97.03
68.90
43.47
50.96
50.22
39.00
45.72
42.00
46.36
Interest
3.29
3.09
3.43
3.42
1.44
1.40
1.41
1.40
1.81
3.10
1.60
Depreciation
37.59
37.30
37.81
37.46
33.24
35.14
34.62
33.73
38.81
24.91
27.90
PBT
225.83
289.39
389.83
320.97
239.80
241.11
257.65
232.62
203.65
218.36
197.72
Tax
57.37
73.23
86.53
80.08
66.85
67.12
63.30
63.48
55.51
83.04
42.55
Tax Rate
25.40%
25.30%
22.32%
24.95%
28.01%
27.84%
25.14%
27.29%
27.26%
38.03%
21.52%
PAT
168.45
216.40
301.33
240.89
171.85
173.99
188.47
169.14
148.15
135.32
155.17
PAT before Minority Interest
168.71
216.16
301.18
240.89
171.85
173.99
188.47
169.14
148.15
135.32
155.17
Minority Interest
0.26
0.24
0.15
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
10.38%
14.16%
22.60%
17.92%
15.76%
16.18%
18.59%
17.01%
16.66%
16.00%
20.08%
PAT Growth
-42.34%
-28.19%
25.09%
40.17%
-1.23%
-7.68%
11.43%
14.17%
9.48%
-12.79%
 
EPS
10.15
13.04
18.16
14.52
10.36
10.49
11.36
10.20
8.93
8.16
9.35

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
1,956.79
1,734.13
1,547.43
1,445.24
1,276.11
1,270.20
1,082.47
936.38
845.30
784.24
Share Capital
16.88
16.88
17.10
17.52
17.52
17.86
17.86
17.86
17.86
18.16
Total Reserves
1,939.91
1,717.25
1,530.33
1,427.72
1,258.59
1,252.34
1,064.61
918.52
827.43
766.08
Non-Current Liabilities
391.17
299.63
314.62
229.17
211.41
216.67
19.93
24.06
30.97
31.32
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.22
Unsecured Loans
0.65
0.72
0.34
0.49
0.60
0.69
0.79
0.90
1.07
1.24
Long Term Provisions
349.81
281.24
295.78
213.96
194.12
198.60
0.50
0.56
0.00
0.00
Current Liabilities
690.40
621.79
564.62
497.43
480.07
389.40
163.42
187.97
195.69
153.97
Trade Payables
136.94
77.28
117.86
77.61
97.32
75.10
82.59
87.17
80.05
61.04
Other Current Liabilities
86.44
77.36
80.06
61.67
68.78
64.11
50.16
36.61
42.87
35.98
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
1.00
1.11
1.14
Short Term Provisions
467.01
467.15
366.69
358.15
313.97
250.19
30.67
63.19
71.66
55.81
Total Liabilities
3,037.93
2,655.38
2,426.67
2,171.84
1,967.59
1,876.27
1,265.82
1,148.41
1,071.96
969.53
Net Block
705.06
689.15
673.50
682.19
673.64
678.05
675.16
393.04
284.40
289.19
Gross Block
949.42
897.55
844.97
817.80
776.49
745.84
708.81
629.67
470.42
453.02
Accumulated Depreciation
244.36
208.40
171.47
135.61
102.84
67.79
33.65
236.62
186.02
163.82
Non Current Assets
1,619.50
1,303.33
1,181.25
1,113.46
976.64
957.93
742.46
646.27
619.47
558.20
Capital Work in Progress
104.82
19.21
23.85
12.38
12.84
6.32
19.92
28.80
18.10
7.22
Non Current Investment
384.73
265.36
162.31
179.11
74.07
54.49
39.43
216.72
186.92
245.15
Long Term Loans & Adv.
424.05
326.65
320.83
239.08
215.28
218.46
7.70
6.37
128.71
15.13
Other Non Current Assets
0.84
2.96
0.75
0.71
0.81
0.60
0.25
1.33
1.33
1.51
Current Assets
1,418.43
1,352.05
1,245.41
1,058.38
990.94
918.34
523.36
502.13
452.03
410.83
Current Investments
500.77
524.84
502.24
405.93
397.16
436.53
285.41
272.49
229.90
170.91
Inventories
304.70
214.92
209.96
173.79
160.49
137.16
130.91
123.22
103.00
99.71
Sundry Debtors
82.17
110.54
123.74
87.53
81.66
76.06
61.94
61.04
59.36
43.23
Cash & Bank
38.66
31.58
32.32
21.26
29.30
28.47
18.02
14.95
23.43
36.50
Other Current Assets
492.13
19.76
26.81
11.32
322.33
240.12
27.10
30.44
36.33
60.49
Short Term Loans & Adv.
480.43
450.41
350.34
358.56
311.65
230.44
20.36
14.77
28.18
48.89
Net Current Assets
728.03
730.26
680.79
560.94
510.87
528.94
359.94
314.16
256.33
256.86
Total Assets
3,037.93
2,655.38
2,426.66
2,171.84
1,967.58
1,876.27
1,265.82
1,148.40
1,071.97
969.53

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
161.65
207.08
250.38
112.43
149.84
154.49
174.30
127.64
149.72
149.94
PBT
289.39
389.85
319.95
237.75
240.63
257.71
232.15
203.65
218.36
197.72
Adjustment
-26.48
-48.34
22.58
-0.21
0.39
-10.88
2.41
-1.40
-7.67
-14.20
Changes in Working Capital
-21.72
-39.42
-7.77
-51.05
-23.24
-19.23
-4.54
-11.78
7.09
4.14
Cash after chg. in Working capital
241.19
302.09
334.77
186.49
217.78
227.60
230.02
190.48
217.79
187.66
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-79.54
-95.01
-84.39
-74.06
-67.94
-70.14
-55.73
-62.84
-68.07
-37.72
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
-2.97
0.00
0.00
0.00
0.00
Cash From Investing Activity
-144.57
-77.15
-98.35
-120.33
20.11
-143.55
-73.05
-88.57
-55.38
-107.18
Net Fixed Assets
-136.84
-45.20
-38.52
-40.93
-36.71
-24.24
-81.62
-169.89
-28.28
-19.51
Net Investments
-95.30
-125.65
-79.51
-113.70
19.79
-166.18
170.44
-72.39
-0.76
-75.95
Others
87.57
93.70
19.68
34.30
37.03
46.87
-161.87
153.71
-26.34
-11.72
Cash from Financing Activity
-9.84
-129.35
-142.00
-0.07
-169.43
0.35
-96.98
-47.76
-75.25
-62.83
Net Cash Inflow / Outflow
7.25
0.58
10.03
-7.96
0.52
11.29
4.27
-8.69
19.09
-20.06
Opening Cash & Equivalents
30.43
29.88
19.92
28.13
27.10
16.25
12.17
23.26
4.17
24.23
Closing Cash & Equivalent
37.73
30.43
29.88
19.92
28.13
27.10
16.25
14.56
23.26
4.17

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
115.92
102.73
90.51
82.86
73.17
71.42
60.87
52.62
47.47
43.30
ROA
7.59%
11.85%
10.48%
8.30%
9.05%
12.00%
14.01%
13.34%
13.26%
16.92%
ROE
11.71%
18.36%
16.10%
12.63%
13.67%
16.02%
16.76%
16.64%
16.63%
21.01%
ROCE
15.78%
23.74%
21.63%
17.64%
19.04%
21.51%
23.15%
23.02%
27.12%
26.85%
Fixed Asset Turnover
1.70
1.57
1.66
1.41
1.42
1.44
1.52
1.65
1.87
1.79
Receivable days
22.35
31.31
27.96
27.55
26.58
23.96
22.06
24.19
21.70
19.72
Inventory Days
60.27
56.79
50.80
54.43
50.15
46.55
45.58
45.45
42.89
46.90
Payable days
73.73
86.01
38.19
40.35
41.32
40.83
44.81
47.89
44.12
40.39
Cash Conversion Cycle
8.89
2.09
40.57
41.62
35.41
29.68
22.84
21.74
20.47
26.23
Total Debt/Equity
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest Cover
94.67
113.90
94.95
166.95
172.62
179.60
167.11
113.30
71.41
124.23

News Update:


  • FDC’s brand ZIFI awarded with Certificate of Excellence at AWACS 2022
    25th Nov 2022, 10:47 AM

    FAVENZA was recognized for New Introduction of the Year in Acute Therapy

    Read More
  • FDC - Quarterly Results
    14th Nov 2022, 18:27 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.